Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1

Journal of Virology

Volumn 79, Issue 8, 2005, Pages 4927-4935

  Poon, B ^a   Safrit, J T ^a,b   McClure, H ^f,g   Kitchen, C ^a,c   Hsu, J F ^a   Gudeman, V ^a   Petropoulos, C ^e   Wrin, T ^e   Chen, I S Y ^a   Grovit Ferbas, K ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e MONOGRAM BIOSCIENCES   (United States)

^f EMORY UNIVERSITY   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; FORMALDEHYDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; QS 21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELL LINE; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; HEATING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMATE; PRIORITY JOURNAL; VACCINATION; VIRION; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS STRAIN;

AIDS VACCINES; ANTIBODY FORMATION; B-LYMPHOCYTES; CELLS, CULTURED; ELECTROPORATION; FORMALDEHYDE; GENE PRODUCTS, ENV; HIV-1; HUMANS; VACCINES, ATTENUATED; VIRUS SHEDDING;

EID: 20144388317     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.8.4927-4935.2005     Document Type: Article

References (46)

1. AIDS Vaccine Evaluation Group. 1999. The AIDS Vaccine Evaluation Group (AVEG) information handbook. Section II. Immunology assays and methods. Clinical Development Branch of the Division of AIDS, National Institute of Allergies and Infectious Diseases, Bethesda, Md. [Online.] http://scharp.org/public/redbook/ contents.htm.
2. Arthur, L. O., J. W. Bess, Jr., R. C. Sowder II, R. E. Benveniste, D. L. Mann, J.-C. Chermann, and L. E. Henderson. 1992. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935-1938.
3. Arthur, L. O., J. W. Bess, Jr., E. N. Chertova, J. L. Rossio, M. T. Esser, R. E. Benveniste, L. E. Henderson, and J. D. Lifson. 1998. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retrovir. 14(Suppl. 3):S311-S319.
4. Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167:4878-4886.
5. Binley, J. M., R. Wyatt, E. Desjardins, P. D. Kwong, W. Hendrickson, J. P. Moore, and J. Sodroski. 1998. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS Res. Hum. Retrovir. 14:191-198.
6. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
7. Burton, D. R., and J. P. Moore. 1998. Why do we not have an HIV vaccine and how can we make one? Nat. Med. 4:495-498.
8. Camerini, D., and B. Seed. 1990. A CD4 domain important for HIV-mediated syncytium formation lies outside the principal virus binding site. Cell 60:747-754.
9. Chackerian, B., E. M. Long, P. A. Luciw, and J. Overbaugh. 1997. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71:3932-3939.
10. Cranage, M. P., N. Polyanskaya, B. McBride, N. Cook, L. A. Ashworth, M. Dennis, A. Baskerville, P. J. Greenaway, T. Corcoran, and P. Kitchin. 1993. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 9:13-22.
11. Dong, M., P. F. Zhang, F. Grieder, J. Lee, G. Krishnamurthy, T. VanCott, C. Broder, V. R. Polonis, X. F. Yu, Y. Shao, D. Faix, P. Valente, and G. V. Quinnan, Jr. 2003. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J. Virol. 77:3119-3130.
12. Einfeld, D., and E. Hunter. 1988. Oligomeric structure of a prototype retrovirus glycoprotein. Proc. Natl. Acad. Sci. USA 85:8688-8692.
13. Fouts, T., K. Godfrey, K. Bobb, D. Montefiori, C. V. Hanson, V. S. Kalyanaraman, A. DeVico, and R. Pal. 2002. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. USA 99:11842-11847.
14. Garlick, R. L., R. J. Kirschner, F. M. Eckenrode, W. G. Tarpley, and C. S. Tomich. 1990. Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. AIDS Res. Hum. Retrovir. 6:465-479.
15. Gorelick, R. J., R. E. Benveniste, T. D. Gagliardi, T. A. Wiltrout, L. K. Busch, W. J. Besehe, L. V. Coren, J. D. Lifson, P. J. Bradley, L. E. Henderson, and L. O. Arthur. 1999. Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain mne produce virions that are replication defective in vitro and in vivo. Virology 253:259-270.
16. Green, T. D., D. C. Montefiori, and T. M. Ross. 2003. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77:2046-2055.
17. Grovit-Ferbas, K., J. Ferbas, V. Gudeman, S. Sadeghi, M. B. Goetz, J. V. Giorgi, I. S. Chen, and W. A. O'Brien. 1998. Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. J. Virol. 72:8650-8658.
18. Grovit-Ferbas, K., J. F. Hsu, J. Ferbas, V. Gudeman, and I. S. Chen. 2000. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J. Virol. 74:5802-5809.
19. Issel, C. J., D. W. Horohov, D. F. Lea, W. V. J. Adams, S. D. Hagius, J. M. McManus, A. C. Allison, and R. C. Montelaro. 1992. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J. Virol. 66:3398-3408.
20. Javaherian, K., R. Khiroya, C. Quinlan, J. G. Boyd, and K. A. Hanham. 1994. V3-mediated heparin neutralization of HIV type 1. AIDS Res. Hum. Retrovir. 10:1421-1423.
21. Jeffs, S. A., C. Shotton, P. Balfe, and J. A. McKeating. 2002. Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol. 83:2723-2732.
22. Kim, Y. B., D. P. Han, C. Cao, and M. W. Cho. 2003. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 305:124-137.
23. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
24. McKeating, J. A., A. McKnight, and J. P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65:852-860.
25. Moore, J. P., and J. Binley. 1998. HIV. Envelope's letters boxed into shape. Nature 393:630-631.
26. Moore, J. P., and R. F. Jarrett. 1988. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res. Hum. Retrovir. 4:369-379.
27. Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142.
28. O'Brien, W. A., S.-H. Mao, Y. Cao, and J. P. Moore. 1994. Macrophagetropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J. Virol. 68:5264-5269.
29. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to envencoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1932-1936.
30. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
31. Pu, R., M. C. Tellier, and J. K. Yamamoto. 1997. Mechanism(s) of FIV vaccine protection. Leukemia 11(Suppl. 3):98-101.
32. Putkonen, P., C. Nilsson, K. Hild, R. Benthin, M. Cranage, A. M. Aubertin, and G. Biberfeld. 1993. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells. J. Med. Primatol. 22:100-103.
33. Quinones-Kochs, M. I., L. Buonocore, and J. K. Rose. 2002. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 76:4199-4211.
34. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
35. Rossio, J. L., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, L. O. Arthur, L. E. Henderson, and J. D. Lifson. 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
36. Ruprecht, R. M., R. Hofmann-Lehmann, B. A. Smith-Franklin, R. A. Rasmussen, V. Liska, J. Vlasak, W. Xu, T. W. Baba, A. L. Chenine, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, D. C. Montefiori, and H. M. McClure. 2001. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol. 8:350-358.
37. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed., p. 16.30-16.40. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
38. Srivastava, I. K., K. VanDorsten, L. Vojtech, S. W. Barnett, and L. Stamatatos. 2003. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77:2310-2320.
39. Stamatatos, L., and C. Cheng-Mayer. 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:6191-6198.
40. Tellier, M. C., J. Soos, R. Pu, D. Pollock, and J. K. Yamamoto. 1997. Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines. Vet. Microbiol. 57:1-11.
41. Tremblay, M. J., J. F. Fortin, and R. Cantin. 1998. The acquisition of host-encoded proteins by nascent HIV-1. Immunol. Today 19:346-351.
42. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
43. Vujcic, L. K., and G. V. Quinnan, Jr. 1995. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res. Hum. Retrovir. 11:783-787.
44. Waite, D. C., E. W. Jacobson, F. A. Ennis, R. Edelman, B. White, R. Kammer, C. Anderson, and C. R. Kensil. 2001. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19:3957-3967.
45. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
46. Zwick, M. B., M. Wang, P. Poignard, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren. 2001. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:12198-12208.